CXCL12 nanoparticles

CXCL12 nanoparticles are a preclinical therapeutic candidate developed by the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital for the treatment of Type 1 Diabetes (T1D). The drug consists of the chemokine CXCL12 (C-X-C motif chemokine ligand 12, also known as stromal cell-derived factor 1 or SDF-1) formulated within or on the surface of nanoparticles. The mechanism of action involves leveraging the immunomodulatory properties of CXCL12 to protect pancreatic beta cells from autoimmune destruction. CXCL12 acts as a ligand for the CXCR4 receptor; in the context of T1D, it is designed to create an 'immunoprivileged' site by promoting the recruitment of regulatory T cells (Tregs) and potentially inducing the chemorepulsion of pathogenic effector T cells away from the islets. This approach aims to preserve endogenous beta cell function or improve the survival of transplanted islet cells without the need for chronic systemic immunosuppression.

Other names

CXCL12 nanoparticlesCXCL-12 nanoparticlesCXCL 12 nanoparticlesSDF-1 nanoparticlesSDF1 nanoparticlesSDF 1 nanoparticlesCXCL12-coated nanoparticlesCXCL-12-coated nanoparticlesCXCL 12-coated nanoparticles